Jonathan S. Wolin - 08 Oct 2024 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
Chief of Staff, Chief Compliance Officer and General Counsel
Signature
/s/ Jonathan S. Wolin, Jonathan S. Wolin
Issuer symbol
JAGX
Transactions as of
08 Oct 2024
Transactions value $
$0
Form type
4
Filing time
10 Oct 2024, 21:57:34 UTC
Previous filing
21 May 2024
Next filing
02 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Award $0 +4,922 +149.15% $0 4,955 08 Oct 2024 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Stock option (right to buy) Award $0 +39,376 $0 39,376 08 Oct 2024 Common Stock 39,376 $1.29 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2 The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024.
F3 Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest in three equal annual installments beginning on October 8, 2025. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice.
F4 On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the " Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
F5 The options will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.

Remarks:

Chief of Staff, Chief Compliance Officer and General Counsel